Collagen-induced arthritis is exacerbated in IL-10-deficient mice

Arthritis Research & Therapy

Alison Finnegan⁴  Charles D Kaplan⁴  Yanxia Cao²  Hermann Eibel¹  Tibor T Glant³  Jian Zhang³ 

[1] Klinische Forschergruppe fur Rheumatologie, Freiburg, Germany

[2] Department of Medicine, Section of Rheumatology, Rush Presbyterian–St Luke's Medical Center, Chicago, Illinois, USA

[3] Department of Orthopedic Surgery and Department of Biochemistry, Rush Presbyterian–St Luke's Medical Center, Chicago, Illinois, USA

[4] Department of Immunology and Microbiology, Rush Presbyterian–St Luke's Medical Center, Chicago, Illinois, USA

关键词: cytokines;    autoimmunity;    arthritis;    antibody;   

Others  :  1101419
DOI  :  10.1186/ar601

 received in 2002-07-11, accepted in 2002-09-11,  发布年份 2002

【 摘 要 】

IL-10 is a potent immunoregulatory cytokine attenuating a wide range of immune effector and inflammatory responses. In the present study, we assess whether endogenous levels of IL-10 function to regulate the incidence and severity of collagen-induced arthritis. DBA/1 wildtype (WT), heterozygous (IL-10^+/-) and homozygous (IL-10^-/-) IL-10-deficient mice were immunized with type II collagen. Development of arthritis was monitored over time, and collagen-specific cytokine production and anticollagen antibodies were assessed. Arthritis developed progressively in mice immunized with collagen, and 100% of the WT, IL-10^+/-, and IL-10^-/- mice were arthritic at 35 days. However, the severity of arthritis in the IL-10^-/- mice was significantly greater than that in WT or IL-1^+/- animals. Disease severity was associated with reduced IFN-γ levels and a dramatic increase in CD11b-positive macrophages. Paradoxically, both the IgG₁ and IgG_2a anticollagen antibody responses were also significantly reduced. These data demonstrate that IL-10 is capable of controlling disease severity through a mechanism that involves IFN-γ. Since IL-10 levels are elevated in rheumatoid arthritis synovial fluid, these findings may have relevance to rheumatoid arthritis.

【 授权许可】

   
2003 Finnegan et al., licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any non-commercial purpose, provided this notice is preserved along with the article's original URL.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Moore KW, O'Garra A, de Waal Malefyt R, Vieira P, Mosmann TR: Interleukin-10. Annu Rev Immunol 1993, 11:165.
• [2]Mosmann TR: Properties and functions of interleukin-10. Adv Immunol 1994, 56:1.
• [3]Fiorentino DF, Zlotnik A, Vieira P, Mosmann TR, Howard M, Moore KW, O'Garra A: IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells. J Immunol 1991, 146:3444.
• [4]O'Garra A, Stapleton G, Dhar V, Pearce M, Schumacher J, Rugo H, Barbis D, Stall A, Cupp J, Moore K, Vierra P, Mosmann T, Whitmore A, Arnold L, Haughton G, Howard M: Production of cytokines by mouse B cells: B lymphomas and normal B cells produce interleukin 10. Int Immunol 1990, 2:821.
• [5]de Waal Malefyt R, Abrams J, Bennett B, Figdor CG, de Vries JE: Interleukin 10 (IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J Exp Med 1991, 174:1209.
• [6]Fiorentino DF, Zlotnik A, Mosmann TR, Howard M, O'Garra A: IL-10 inhibits cytokine production by activated macrophages. J Immunol 1991, 147:3815.
• [7]de Waal Malefyt R, Haanen J, Spits H, Roncarolo MG, te Velde A, Figdor C, Johnson K, Kastelein R, Yssel H, de Vries JE: Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression. J Exp Med 1991, 174:915.
• [8]Willems F, Marchant A, Delville JP, Gerard C, Delvaux A, Velu T, de Boer M, Goldman M: Interleukin-10 inhibits B7 and intercellular adhesion molecule-1 expression on human monocytes. Eur J Immunol 1994, 24:1007.
• [9]Song S, Ling-Hu H, Roebuck KA, Rabbi MF, Donnelly RP, Finnegan A: Interleukin-10 inhibits interferon-gamma-induced intercellular adhesion molecule-1 gene transcription in human monocytes. Blood 1997, 89:4461.
• [10]Ding L, Linsley PS, Huang LY, Germain RN, Shevach EM: IL-10 inhibits macrophage costimulatory activity by selectively inhibiting the up-regulation of B7 expression. J Immunol 1993, 151:1224.
• [11]D'Andrea A, Aste-Amezaga M, Valiante NM, Ma X, Kubin M, Trinchieri G: Interleukin 10 (IL-10) inhibits human lymphocyte interferon gamma-production by suppressing natural killer cell stimulatory factor/IL-12 synthesis in accessory cells. J Exp Med 1993, 178:1041.
• [12]Macatonia SE, Hosken NA, Litton M, Vieira P, Hsieh CS, Culpepper JA, Wysocka M, Trinchieri G, Murphy KM, O'Garra A: Dendritic cells produce IL-12 and direct the development of Th1 cells from naive CD4+ T cells. J Immunol 1995, 154:5071.
• [13]Bogdan C, Vodovotz Y, Nathan C: Macrophage deactivation by interleukin 10. J Exp Med 1991, 174:1549.
• [14]Gazzinelli RT, Oswald IP, James SL, Sher A: IL-10 inhibits parasite killing and nitrogen oxide production by IFN-gamma-activated macrophages. J Immunol 1992, 148:1792.
• [15]Cassatella MA, Meda L, Gasperini S, Calzetti F, Bonora S: Interleukin 10 (IL-10) upregulates IL-1 receptor antagonist production from lipopolysaccharide-stimulated human polymorphonuclear leukocytes by delaying mRNA degradation. J Exp Med 1994, 179:1695.
• [16]Katsikis PD, Chu CQ, Brennan FM, Maini RN, Feldmann M: Immunoregulatory role of interleukin 10 in rheumatoid arthritis. J Exp Med 1994, 179:1517.
• [17]Cush JJ, Splawski JB, Thomas R, McFarlin JE, Schulze-Koops H, Davis LS, Fujita K, Lipsky PE: Elevated interleukin-10 levels in patients with rheumatoid arthritis. Arthritis Rheum 1995, 38:96.
• [18]van Roon JA, van Roy JL, Gmelig-Meyling FH, Lafeber FP, Bijlsma JW: Prevention and reversal of cartilage degradation in rheumatoid arthritis by interleukin-10 and interleukin-4. Arthritis Rheum 1996, 39:829.
• [19]Walmsley M, Katsikis PD, Abney E, Parry S, Williams RO, Maini RN, Feldmann M: Interleukin-10 inhibition of the progression of established collagen-induced arthritis. Arthritis Rheum 1996, 39:495.
• [20]Tanaka Y, Otsuka T, Hotokebuchi T, Miyahara H, Nakashima H, Kuga S, Nemoto Y, Niiro H, Niho Y: Effect of IL-10 on collagen-induced arthritis in mice. Inflamm Res 1996, 45:283.
• [21]Persson S, Mikulowska A, Narula S, O'Garra A, Holmdahl R: Interleukin-10 suppresses the development of collagen type II-induced arthritis and ameliorates sustained arthritis in rats. Scand J Immunol 1996, 44:607.
• [22]Joosten LA, Lubberts E, Durez P, Helsen MM, Jacobs MJ, Goldman M, van den Berg WB: Role of interleukin-4 and interleukin-10 in murine collagen-induced arthritis. Protective effect of interleukin-4 and interleukin-10 treatment on cartilage destruction. Arthritis Rheum 1997, 40:249.
• [23]Ma Y, Thornton S, Duwel LE, Boivin GP, Giannini EH, Leiden JM, Bluestone JA, Hirsch R: Inhibition of collagen-induced arthritis in mice by viral IL-10 gene transfer. J Immunol 1998, 161:1516.
• [24]Apparailly F, Verwaerde C, Jacquet C, Auriault C, Sany J, Jorgensen C: Adenovirus-mediated transfer of viral IL-10 gene inhibits murine collagen-induced arthritis. J Immunol 1998, 160:5213.
• [25]Kuhn R, Lohler J, Rennick D, Rajewsky K, Muller W: Interleukin-10-deficient mice develop chronic enterocolitis [see comments]. Cell 1993, 75:263.
• [26]Stoop R, Kotani H, McNeish JD, Otterness IG, Mikecz K: Increased resistance to collagen-induced arthritis in CD44-deficient DBA/1 mice. Arthritis Rheum 2001, 44:2922.
• [27]Glant TT, Mikecz K, Arzoumanian A, Poole AR: Proteoglycan-induced arthritis in BALB/c mice. Clinical features and histopathology. Arthritis Rheum 1987, 30:201.
• [28]Finnegan A, Needleman B, Hodes RJ: Activation of B cells by autoreactive T cells: cloned autoreactive T cells activate B cells by two distinct pathways. J Immunol 1984, 133:78.
• [29]Mikecz K, Glant TT, Buzas E, Poole AR: Proteoglycan-induced polyarthritis and spondylitis adoptively transferred to naive (nonimmunized) BALB/c mice. Arthritis Rheum 1990, 33:866.
• [30]Finnegan A, Mikecz K, Tao P, Glant TT: Proteoglycan (Aggrecan)-induced arthritis in BALB/c mice is a Th1-type disease regulated by Th2 cytokines. J Immunol 1999, 163:5383.
• [31]Stuart JM, Dixon FJ: Serum transfer of collagen-induced arthritis in mice. J Exp Med 1983, 158:378.
• [32]Go NF, Castle BE, Barrett R, Kastelein R, Dang W, Mosmann TR, Moore KW, Howard M: Interleukin 10, a novel B cell stimulatory factor: unresponsiveness of X chromosome-linked immunodeficiency B cells. J Exp Med 1990, 172:1625.
• [33]Pecanha LM, Snapper CM, Lees A, Mond JJ: Lymphokine control of type 2 antigen response. IL-10 inhibits IL-5- but not IL-2-induced Ig secretion by T cell-independent antigens. J Immunol 1992, 148:3427.
• [34]Vermeire K, Heremans H, Vandeputte M, Huang S, Billiau A, Matthys P: Accelerated collagen-induced arthritis in IFN-gamma receptor-deficient mice. J Immunol 1997, 158:5507.
• [35]Manoury-Schwartz B, Chiocchia G, Bessis N, Abehsira-Amar O, Batteux F, Muller S, Huang S, Boissier MC, Fournier C: High susceptibility to collagen-induced arthritis in mice lacking IFN-gamma receptors. J Immunol 1997, 158:5501.
• [36]Matthys P, Vermeire K, Mitera T, Heremans H, Huang S, Schols D, De Wolf-Peeters C, Billiau A: Enhanced autoimmune arthritis in IFN-gamma receptor-deficient mice is conditioned by mycobacteria in Freund's adjuvant and by increased expansion of Mac-1+ myeloid cells. J Immunol 1999, 163:3503.
• [37]Johansson AC, Hansson AS, Nandakumar KS, Backlund J, Holmdahl R: IL-10-deficient B10.Q mice develop more severe collagen-induced arthritis, but are protected from arthritis induced with anti-type II collagen antibodies. J Immunol 2001, 167:3505.
• [38]Ortmann RA, Shevach EM: Susceptibility to collagen-induced arthritis: cytokine-mediated regulation. Clin Immunol 2001, 98:109.
• [39]Cuzzocrea S, Mazzon E, Dugo L, Serraino I, Britti D, De Maio M, Caputi AP: Absence of endogeneous interleukin-10 enhances the evolution of murine type-II collagen-induced arthritis. Eur Cytokine Network 2001, 12:568.
• [40]Ferber IA, Brocke S, Taylor-Edwards C, Ridgway W, Dinisco C, Steinman L, Dalton D, Fathman CG: Mice with a disrupted IFN-gamma gene are susceptible to the induction of experimental autoimmune encephalomyelitis (EAE). J Immunol 1996, 156:5.
• [41]Boissier MC, Chiocchia G, Bessis N, Hajnal J, Garotta G, Nicoletti F, Fournier C: Biphasic effect of interferon-gamma in murine collagen-induced arthritis. Eur J Immunol 1995, 25:1184.
• [42]Kennedy SM, Borch RF: IL-1beta mediates diethyldithiocarbamate-induced granulocyte colony-stimulating factor production and hematopoiesis. Exp Hematol 1999, 27:210.
• [43]Snapper CM, Paul WE: Interferon-gamma and B cell stimulatory factor-1 reciprocally regulate Ig isotype production. Science 1987, 236:944.